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Abstract 
The aim of this study was to evaluate the effects of vaccination against gonadotropin-
releasing factor (GnRF) on testicular development, testosterone secretion and physical 
activity in pubertal bulls. The experiment was performed using 44 bulls aged between 6 and 7 
months. Twenty-three animals were vaccinated twice 4 weeks apart with 1 mL of Bopriva® 
(Pfizer Animal Health, Australia) and 21 bulls served as matched controls. Serum GnRF 
antibody titer and testosterone concentration as well as body weight and scrotal circumference 
were determined in all bulls for 24 weeks from the first vaccination. In addition, physical 
activity was analyzed in 11 vaccinated and in 10 control animals using the ALPRO DeLaval 
activity meter system (DeLaval AG, Sursee, Switzerland). The results show that vaccination 
significantly (P < 0.05) influenced all parameters evaluated except body weight. Antibody 
2 
 
titers to GnRF began to rise 2 weeks after the first vaccination and reached peak values 2 
weeks after the second injection. Significant group differences in anti-GnRF titer were present 
for 22 weeks following the first vaccination. Testosterone concentrations were significantly 
lower between weeks 6 to 24 after first vaccination in bulls with Bopriva® compared to 
control animals. In vaccinated bulls testicular development was impaired after the second 
injection and scrotal circumference was significantly smaller between weeks 8 to 24 after first 
vaccination. Physical activity of vaccinated bulls was reduced after the booster injection with 
significant group differences for a continuous period of 106 days. In conclusion, vaccination 
against GnRF with Bopriva® in pubertal bulls decreased testosterone levels in peripheral 
blood, testicular development and physical activity but did not affect weight gain. 
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1. Introduction 
Immunization against gonadotropin-releasing factor (GnRF) represents an animal-friendly 
alternative to physical castration in male and female mammals [1,2]. The suppression of 
reproductive function using an anti-GnRF vaccine has been demonstrated in numerous studies 
in cattle [3-13], sheep [10,14-21], pig [22-28], horse [29-34] and in wild animals [35-39]. 
The first commercial available vaccine against GnRF (Vaxstrate, Peptide Technology Ltd, 
N.S.W., Australia) was approved in Australia for suppression of estrus in heifers [8]. Because 
of severe adverse reactions and short duration of effect in the field, Vaxstrate was withdrawn 
from the market in 1996. In 1998, Improvac (Pfizer, Animal Health, Australia) was 
introduced to the market for immunocastration of male pigs and served as a scientific 
platform for the development of the horse-specific anti-GnRF vaccine Equity (Pfizer, 
Animal Health, Australia). Since 2007, a new vaccine (Bopriva, Pfizer, Animal Health, 
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Australia) designed specifically for cattle, has been registered in New Zealand and Australia 
for the reduction of testosterone blood levels in pubertal bulls. Currently Bopriva  is the only 
anti-GnRF vaccine available for cattle on the market and has demonstrated good efficacy and 
safety in a pilot project [13] with young bulls. The latter and several other studies 
[6,9,20,40,41] have shown that anti-GnRF based vaccines to be efficacious at suppressing 
testosterone driven sexual and aggressive behavior. In these investigations behavior was only 
assessed subjectively but no information is available in the literature about behavior changes 
in vaccinated bulls analyzed objectively by using an electronic activity meter system. Thus, 
the aim of the present study was to evaluate the effects of the new commercially available 
cattle specific vaccine Bopriva on testicular development, testosterone secretion and 
physical activity in fattening bulls of dairy breeds, housed in small groups and supplied with a 
high energy diet. 
 
2. Material and methods 
2.1. Experimental design 
For this experiment a total of 44 dairy bulls calves (Holstein Friesian and Red Holstein n = 
21, Brown Swiss n = 23) of one month of age were obtained from different farms. They were 
housed in groups and fed skim powder-based milk replacer ad libitum with free access to 
water, hay, straw as well as minerals for 8 weeks until weaning. Thereafter, the animals were 
kept in an open free stall barn divided into 4 separate pens of 10 to 12 animals each, and a 
high-energy finishing diet was provided. At an age between 6 and 7 months and a mean (± 
SD) body weight of 228 ± 37.7 kg bulls from 2 pens were allocated to a treatment group (n = 
23) and animals from the other 2 pens (n = 21) served as controls. Bulls in the treatment 
group were vaccinated twice 4 weeks apart with 1 mL Bopriva® (400 μg GnRF-protein 
conjugate, Pfizer Animal Health, Australia) subcutaneously on the neck. Control animals 
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received the same amount of saline solution. Treatment effects were evaluated for the 
duration of 6 months and animals examined every 2 weeks. At each occasion bulls were 
weighed, scrotal circumference measured (ReliaBull®, Lane Manufacturing Inc., Denver, 
USA) and blood collected by venipuncture of the Vena coccygealis ventralis using 
vacutainers (9 mL Z Serum Clot Activator® Vacuette®, Greiner Bio-One GmbH, 
Kremsmünster, Austria). The blood samples were allowed to clot during 2 h at room 
temperature and after centrifugation (4000 x g, 10 min) serum was decanted and frozen (-18 
°C) until analysis. To monitor physical activity, one pen with vaccinated bulls (n = 11) and 
one pen with control animals (n = 10) were equipped with an electronic activity measurement 
system and activity data was recorded from day -3 to day 190 after first vaccination. All 
animal experimentation was performed following approval from the local Animal Ethics 
Committee. 
 
2.2. Determination of physical activity 
Physical activity was analyzed using the ALPRO DeLaval activity meter system (DeLaval 
AG, Sursee, Switzerland). The system was developed to register an increase in activity of 
cattle approaching heat [42]. It consists of an activity tag (including a mobile ball and an 
activity-sensing transponder), a remote-antenna, and a receiver connected to a processor 
interfaced with a computer equipped with ALPRO DeLaval herd management software 
(DeLaval AG, Sursee, Switzerland). The activity tag mounted on a collar emits a signal every 
14 sec if the ball inside the tag is moving (1) or not moving (0). Thus, reliable registration of 
locomotion and movements of the head of the animal is possible. Signals are monitored, and 
hourly activity (maximal activity 256) data transmitted via antenna to the receiver/processor, 
which then sends the data to the computer.  
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2.3. Hormone analysis and anti-GnRF antibody titers 
Anti-GnRF antibody titers 
Serum anti-GnRF antibody titers were determined by dissociation enhanced lanthanide 
fluorescence immunoassay (DELFIA) (Perkin Elmer Pty Ltd, Glen Waverly, Australia). 
Briefly, 384-well streptavidin coated plates (Perkin Elmer Pty Ltd, Glen Waverly, Australia) 
were coated for 1 h at room temperature with 1 µg/mL biotinylated GnRF peptide in DELFIA 
buffer (50mM Tris-HCl, 0.9 % NaCl, 0.05 % Tween 20, 20 µM EDTA, 0.2 % ovalbumin). 
Plates were washed and then incubated with serial dilutions of test cattle serum for 1 h at 
room temperature. Unbound serum and antibodies were removed by washing, and bound 
antibody was detected by incubating plates for a further 1 h with europium labeled protein G 
(Perkin Elmer Pty Ltd, Glen Waverly, Australia). After washing off excess europium labeled 
protein G, DELFIA Enhancement Solution (Perkin Elmer Pty Ltd, Glen Waverly, Australia) 
was added to all wells. After 10 min plates were excited at 340 nm and emission at 615 nm 
measured. Serial dilutions of a standard with a nominal titer of 1/409’600 served as a 
reference for unknown samples. Non-vaccinated cattle serum served as a negative control. 
Testosterone concentrations 
Testosterone was determined by enzyme-amplified sensitivity immunoassay (TESTO-EASIA, 
BioSource Europe S.A, Nivelles, Belgium). The detection limit of the assay was 0.01 ng/mL. 
All samples were analyzed using a competitive binding assay where a fixed amount of 
testosterone labeled with horseradish peroxidase (HRP) compete with unlabelled testosterone 
present in calibrators, controls and samples. Cross reactivity with estrogens and progesterone 
was 0.023 % and 0.035 %, respectively, with androstenedione 0.76 % and 5-α-
dihydrotestosterone 0.61 %. The intra- and inter-assay coefficients of variance were 6.3 % 
and 8.3 %, respectively. 
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2.4. Statistical analysis 
Statistical analysis was performed using the StatView 5.0 software program (SAS Institut, 
Dübendorf, Switzerland). A multivariate analysis of variance (ANOVA) with repeated 
measurements was carried out to assess the effects of group, time of examination and the 
interaction of group and time on the various parameters. For assessment of bull activity the 
mean hourly activity per day was considered. Multiple comparisons were performed after 
Bonferroni adjustment. Non-normally distributed data were log-transformed for this purpose. 
Values were considered to be statistical significant at P < 0.05. 
 
3. Results 
3.1. Effects of vaccination 
Group, time of examination and the interaction of group and time significantly (P < 0.05) 
influenced all parameters with exception of body weight, which was significantly influenced 
only by the time of examination. 
 
Anti-GnRF titer 
Mean (± SEM) serum anti-GnRF antibody titers in bulls with and without Bopriva for 24 
weeks after first vaccination are shown in Figure 1a. Significant differences between groups 
were apparent from weeks 2 to 24. 
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Testosterone 
Mean (± SEM) serum testosterone concentrations in bulls with and without Bopriva were 
followed for 24 weeks after first immunization as shown in Figure 1b. Significant differences 
between groups were noted for weeks 6 to 24. 
 
Scrotal circumference 
Mean (± SEM) scrotal circumference in bulls with and without Bopriva were followed for 24 
weeks after first immunization as shown in Figure 1c. Significant differences between groups 
were present at weeks 8 to 24. 
 
Body weight 
Mean (± SEM) body weight in bulls with and without Bopriva during 24 weeks after first 
vaccination is shown in Figure 1d. The weight gain was similar in both groups and no 
significant (P > 0.05) differences were present at any time. 
 
Physical activity 
Measurement of activity levels in bulls using the ALPRO DeLaval meter system provided 
data showing clear and significant differences between groups. Mean (± SEM) hourly activity 
per day in bulls with and without Bopriva was followed from day -3 until day 190 after first 
vaccination as shown in Figure 2. After the booster injection activity was always lower in 
vaccinated compared to control bulls and significant group differences were noted for a period 
of 106 days. 
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Fig. 1. Means (± SEM) of anti-GnRF titer (a), serum testosterone concentration (b), scrotal 
circumference (c) and body weight (d) in bulls with (, n=23) and without (, n=21) 
Bopriva®. Arrows indicate injections. *Significant (P < 0.05) difference between groups. 
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Fig. 2. Mean (± SEM) hourly activity per day in bulls with (, n=23) and without (, n=21) 
Bopriva®. Arrows indicate injections. *Significant (P < 0.05) difference between groups. 
 
4. Discussion 
This study has shown that vaccination against GnRF with the cattle specific vaccine Bopriva® 
effectively suppressed testicular development and testosterone secretion in pubertal bulls for 
at least 12 weeks. Moreover, vaccinated bulls displayed reduced physical activity but similar 
weight gain when compared to control animals. 
As it has been shown in many investigations published during the last years [3-10,17,20,29-
34] vaccination against GnRF was able to induce an increase in anti-GnRF antibody titer. 
When using the specific cattle vaccine Bopriva® as in the present experiment all vaccinated 
animals showed a strong immune response after the 2 injection. The observed pattern and the 
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peak values of anti-GnRF titers as well as the suppression of testosterone secretion were 
comparable to the previous pilot study [13] also using Bopriva® in pubertal bulls aged 
between 6 and 8 months. When comparing these data with a recent experiment [20] using bull 
calves vaccinated at an early age of 3 to 6 weeks, mean maximum titer concentration and the 
duration of testosterone suppression in the older bulls were reduced by approximately half. 
This suggests that calves as young as 3 weeks are able to produce the same or even a better 
immune response than older animals, as also reported by Chase et al. [43]. 
Concomitant with the inhibition of testosterone secretion in vaccinated animals was 
suppression of testicular growth and scrotal circumference. Testes began to grow again when 
testosterone secretion started to increase at 12 weeks after the second vaccination. However, 
the increase in scrotal circumference was less pronounced and remained always lower than in 
control animals. At the end of the study, 20 weeks after the second vaccination, the difference 
between vaccinated and control animals was still 9 cm. The observation that vaccination 
against GnRF resulted in an impairment of testicular development was also found in previous 
studies in pubertal [4,13] as well as prepubertal [6,20] bulls. In the pilot experiment [13] using 
Bopriva®, calves were slaughtered 3 months after the booster vaccination and histological 
examination of testes performed. Vaccinated bulls showed incomplete spermatogenesis with 
impaired or no production of spermatids and a reduced diameter of the seminiferous tubules. 
Moreover a recent study [20] demonstrated that all bulls slaughtered 62 weeks after the 
second vaccination regained spermatogenic capacity reflected by a total sperm count of more 
than 3 x 109 and sperm motility between 26 and 68 % in semen harvested from the 
epididymides. From these results it may be concluded that for sustained inhibition of 
reproduction in bulls revaccination is necessary when testes begin to grow again or 
testosterone related male behavior starts to be expressed. 
Although it is known that testosterone has an anabolic effect, weight gain of vaccinated bulls 
which had low testosterone levels did not differ from control animals what is consistent with 
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findings of previous studies [3-6,11,20]. This may be explained by the reduced physical 
activity in vaccinated animals improving their body condition. Moreover it must be 
considered, that bulls vaccinated against GnRF have carcass characteristics similar to steers 
and better feed efficiency than untreated bulls [4] thus increasing economic return to the beef 
producer.  
In this experiment the ALPRO DeLaval electronic activity meter system has been proven to 
be very well-suited to detect differences in activity between vaccinated and non-vaccinated 
bulls. Compared to control animals, the physical activity of bulls treated with Bopriva® was 
significantly reduced during a total of 106 days after the booster injection. The lowest 
activities occurred 2 days after both the first and second injection indicating a temporary 
apathy caused by the vaccination. From previous studies with Bopriva® [13,20] it has been 
shown that body temperature increased for 1-2 days after both vaccinations without 
displaying any clinical signs of apathy. The above observations indicate that the ALPRO 
DeLaval activity meter system represents a very sensitive tool to detect behavioral changes in 
bulls and confirm the results of earlier studies where behavior of vaccinated animals was 
subjectively assessed [6,9,13,20,40,41]. In this regard Jago et al. [9] found that bulls 
vaccinated with the GnRF vaccine Vaxstrate showed reduced homosexual mounting, 
agonistic behavior and damage to pasture, and concluded that immunocastration could 
provide a practical alternative to traditional methods for bull behavior control. 
In conclusion, this study demonstrated that vaccination against GnRF with Bopriva® in 
pubertal bulls aged between 6 and 7 months led to marked delay in testicular development 
and to a sustained reduction in physical activity but did not affect weight gain. 
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